Glioblastoma clinical trials at UCSD
13 in progress, 4 open to eligible people
Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
open to eligible people ages 18 years and up
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent…
La Jolla, California and other locations
Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
La Jolla, California and other locations
Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
open to eligible people ages 18 years and up
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy vs. the usual chemotherapy alone (temozolomide) in…
La Jolla, California and other locations
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
open to all eligible people
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
La Jolla, California and other locations
Comparing Niraparib with Temozolomide in Adult Participants with Newly-diagnosed, MGMT Unmethylated Glioblastoma
Sorry, not currently recruiting here
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does…
La Jolla, California and other locations
Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS.…
San Diego, California and other locations
Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
Sorry, currently not accepting new patients, but might later
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes…
La Jolla, California and other locations
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by…
La Jolla, California and other locations
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
Sorry, in progress, not accepting new patients
This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500…
San Diego, California and other locations
ICT-107 in Glioblastoma
Sorry, currently not accepting new patients, but might later
ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to…
La Jolla, California and other locations
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM
Sorry, in progress, not accepting new patients
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance…
La Jolla, California and other locations
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sorry, in progress, not accepting new patients
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different …
La Jolla, California and other locations
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Sorry, in progress, not accepting new patients
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated…
La Jolla, California and other locations
Our lead scientists for Glioblastoma research studies include Jessica Schulte, MD PhD David E. Piccioni.
Last updated: